Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Erik H, Jakobsen"'
Autor:
Alan Celik, Tobias Berg, Magnus Gibson, Maj-Britt Jensen, Iben Kümler, Saskia Eßer-Naumann, Erik H. Jakobsen, Ann Knoop, Dorte Nielsen
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: Capecitabine can be used as first-line treatment for advanced breast cancer. However, real-world data on efficacy of capecitabine in this setting is sparse. The purpose of the study is to evaluate outcomes of patients with Hum
Externí odkaz:
https://doaj.org/article/9a4a0d4feb1344fe96950898f4981baa
Autor:
Tobias Berg, Maj-Britt Jensen, Erik H. Jakobsen, Sami Al-Rawi, Julia Kenholm, Michael Andersson
Publikováno v:
Breast, Vol 54, Iss , Pp 242-247 (2020)
Background: Dual blockade with trastuzumab and pertuzumab combined with neoadjuvant chemotherapy (NACT) has been increasingly used for HER2-positive tumours >2 cm and/or with positive axillary lymph nodes in order to evaluate pathologic response and
Externí odkaz:
https://doaj.org/article/722637200726489eb250c0f0ca29f455
Autor:
Jean-Pierre Ayoub, Hans Wildiers, Michael Friedlander, Banu K. Arun, Hyo S. Han, Shannon Puhalla, Yaroslav Shparyk, Erik H. Jakobsen, Meijing Wu, Bruce A. Bach, Dai Feng, Christine K. Ratajczak, David Maag, Véronique Diéras
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Purpose: To evaluate efficacy and safety of veliparib combined with carboplatin/paclitaxel in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, germline BRCA (g BRCA )-associated breast cancer defined by hormone recepto
Externí odkaz:
https://doaj.org/article/d8929c71e59443b4b9a8ed5f5ca93ab6
Autor:
Birgitte V, Offersen, Jan, Alsner, Hanne M, Nielsen, Erik H, Jakobsen, Mette H, Nielsen, Lars, Stenbygaard, Anders N, Pedersen, Mette S, Thomsen, Esben, Yates, Martin, Berg, Ebbe L, Lorenzen, Ingelise, Jensen, Mirjana, Josipovic, Maj-Britt, Jensen, Jens, Overgaard
Publikováno v:
Offersen, B V, Alsner, J, Nielsen, H M, Jakobsen, E H, Nielsen, M H, Stenbygaard, L, Pedersen, A N, Thomsen, M S, Yates, E, Berg, M, Lorenzen, E L, Jensen, I, Josipovic, M, Jensen, M-B, Overgaard, J & Danish Breast Cancer Group Radiotherapy Committee 2022, ' Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial : The Danish Breast Cancer Group Partial Breast Irradiation Trial ', Journal of Clinical Oncology, vol. 40, no. 36, JCO2200451, pp. 4189-4197 . https://doi.org/10.1200/JCO.22.00451
Offersen, B V, Alsner, J, Nielsen, H M, Jakobsen, E H, Nielsen, M H, Stenbygaard, L, Pedersen, A N, Thomsen, M S, Yates, E, Berg, M, Lorenzen, E L, Jensen, I, Josipovic, M, Jensen, M B, Overgaard, J & Danish Breast Cancer Group Radiotherapy Committee 2022, ' Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial : The Danish Breast Cancer Group Partial Breast Irradiation Trial ', Journal of Clinical Oncology, vol. 40, no. 36, pp. 4189-4197 . https://doi.org/10.1200/JCO.22.00451
Offersen, B V, Alsner, J, Nielsen, H M, Jakobsen, E H, Nielsen, M H, Stenbygaard, L, Pedersen, A N, Thomsen, M S, Yates, E, Berg, M, Lorenzen, E L, Jensen, I, Josipovic, M, Jensen, M B, Overgaard, J & Danish Breast Cancer Group Radiotherapy Committee 2022, ' Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial : The Danish Breast Cancer Group Partial Breast Irradiation Trial ', Journal of Clinical Oncology, vol. 40, no. 36, pp. 4189-4197 . https://doi.org/10.1200/JCO.22.00451
PURPOSE On the basis of low risk of local recurrence in elderly patients with breast cancer after conservative surgery followed by whole breast irradiation (WBI), the Danish Breast Cancer Group initiated the noninferiority external-beam partial breas
Autor:
Hope Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N. Schwartz, Timothy Pluard, Francesco Ricci, William Gwin, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Emily Ashley, Shengyan Hong, Minori Rosales, William J. Gradishar
Publikováno v:
Cancer Research. 82:PD8-01
Background: CTX + dual HER2-targeting monoclonal antibodies (mAb) remains a standard of care for treatment (Tx) of both HER2+ early-stage and MBC. However, when the SOPHIA trial was launched, limited Tx options existed after progression on T, pertuzu
Autor:
Jean-Pierre Ayoub, Hans Wildiers, Michael Friedlander, Banu K. Arun, Hyo S. Han, Shannon Puhalla, Yaroslav Shparyk, Erik H. Jakobsen, Meijing Wu, Bruce A. Bach, Dai Feng, Christine K. Ratajczak, David Maag, Véronique Diéras
Publikováno v:
Therapeutic Advances in Medical Oncology. 13:175883592110596
Purpose: To evaluate efficacy and safety of veliparib combined with carboplatin/paclitaxel in patients with advanced human epidermal growth factor receptor 2 (HER2)-negative, germline BRCA (g BRCA)-associated breast cancer defined by hormone receptor
Autor:
Erik H Jakobsen, Charlotte Toftmann Hansen, Kent Søe, Henrik B Jørgensen, Torben Plesner, Jean-Marie Delaissé
Publikováno v:
Journal of Bone and Mineral Research. 28:1738-1750
Zoledronic acid (Zol) is used to treat bone disease in both multiple myeloma (MM) and breast cancer patients with bone metastasis (BC). However, bones of MM and BC patients show a difference in retention of the bisphosphonate used for bone scintigrap
Autor:
Kent, Søe, Torben, Plesner, Erik H, Jakobsen, Charlotte T, Hansen, Henrik B, Jørgensen, Jean-Marie, Delaissé
Publikováno v:
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 28(8)
Zoledronic acid (Zol) is used to treat bone disease in both multiple myeloma (MM) and breast cancer patients with bone metastasis (BC). However, bones of MM and BC patients show a difference in retention of the bisphosphonate used for bone scintigrap